Evidence map›Paper›PMID 27486309›Full record

ArticleDrug design, development and therapy2016

Prediction of selective estrogen receptor beta agonist using open data and machine learning approach.

Ai-Qin Niu, Liang-Jun Xie, Hui Wang, Bing Zhu, Sheng-Qi Wang

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review ofFrontiers in endocrinology · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ai-Qin NiuDepartment of Gynecology, the First People's Hospital of Shangqiu, Shangqiu, Henan, People's Republic of China.
Liang-Jun XieDepartment of Image Diagnoses, the Third Hospital of Jinan, Jinan, Shandong, People's Republic of China.
Hui WangDepartment of Gynecology, the First People's Hospital of Shangqiu, Shangqiu, Henan, People's Republic of China.
Bing ZhuDepartment of Gynecology, the First People's Hospital of Shangqiu, Shangqiu, Henan, People's Republic of China.
Sheng-Qi WangDepartment of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Shangqiu First People's Hospital · CNFourth People’s Hospital of Jinan · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEstrogen receptors (ERs) are nuclear transcription factors that are involved in the regulation of many complex physiological processes in humans. ERs have been validated as important drug targets for the treatment of various diseases, including breast cancer, ovarian cancer, osteoporosis, and cardiovascular disease. ERs have two subtypes, ER-α and ER-β. Emerging data suggest that the development of subtype-selective ligands that specifically target ER-β could be a more optimal approach to elicit beneficial estrogen-like activities and reduce side effects.

methodsHerein, we focused on ER-β and developed its in silico quantitative structure-activity relationship models using machine learning (ML) methods.

resultsThe chemical structures and ER-β bioactivity data were extracted from public chemogenomics databases. Four types of popular fingerprint generation methods including MACCS fingerprint, PubChem fingerprint, 2D atom pairs, and Chemistry Development Kit extended fingerprint were used as descriptors. Four ML methods including Naïve Bayesian classifier, k-nearest neighbor, random forest, and support vector machine were used to train the models. The range of classification accuracies was 77.10% to 88.34%, and the range of area under the ROC (receiver operating characteristic) curve values was 0.8151 to 0.9475, evaluated by the 5-fold cross-validation. Comparison analysis suggests that both the random forest and the support vector machine are superior for the classification of selective ER-β agonists. Chemistry Development Kit extended fingerprints and MACCS fingerprint performed better in structural representation between active and inactive agonists.

conclusionThese results demonstrate that combining the fingerprint and ML approaches leads to robust ER-β agonist prediction models, which are potentially applicable to the identification of selective ER-β agonists.

Indexed as

Databases, FactualMachine LearningComputer SimulationDrug DiscoveryEstrogen Receptor betaHumansOpen Access PublishingQuantitative Structure-Activity RelationshipEstrogen Receptor betaestrogen receptor subtype βmachine learning approachquantitative structure-activity relationship modelsselective estrogen receptor modulators

Identifiers

PMID27486309
PMCPMC4958355
OpenAlexW2496675672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.